A single injection administered just twice a year promises to fundamentally transform HIV prevention strategies across Latin America. The Pan American Health Organization and pharmaceutical giant Gilead Sciences have finalized a landmark agreement designed to enable 14 countries across the region to procure lenacapavir, opening a direct pathway for public distribution of this highly effective injectable pre-exposure prophylaxis method.
The urgency driving this initiative stems from troubling epidemiological figures recorded over the past decade. Publicly available metrics from PAHO demonstrate that new annual HIV diagnoses across Latin America climbed 13 percent between 2010 and 2024, rising from 110,000 to roughly 120,000 cases each year. This upward surge stands in stark contrast to the Caribbean basin, where transmission rates have steadily declined over the same timeframe.
Overcoming Obstacles in Global Generic Licensing
The Latin American nations included in this joint purchasing arrangement are Argentina, Brazil, Chile, Colombia, Costa Rica, Ecuador, El Salvador, Guatemala, Mexico, Panama, Paraguay, Peru, Uruguay, and Venezuela. Health ministries in these participating states will be able to acquire the medication through PAHO's long-standing regional collective buying platforms, specifically its Strategic Fund for essential medicines and its Regional Revolving Funds.
The preventive treatment, authorized by US health regulators under the commercial name Yeztugo, achieved extraordinary efficacy metrics during its phase 3 clinical evaluations. Throughout the pivotal PURPOSE 1 trial, researchers observed zero HIV acquisitions among more than 2,000 young female participants who received the biannual regimen.
This regional pact resolves a critical structural omission present in earlier global distribution plans. When Gilead established voluntary licensing deals in late 2024 with six generic manufacturing firms located in India, Egypt, and Pakistan, the arrangement covered 120 low-income and lower-middle-income countries. However, that agreement excluded most middle-income Latin American nations, leaving countries with heavy disease burdens unable to purchase affordable generic alternatives.
Statistical Discrepancies and Regional Demographics
Discrepancies in regional metrics highlight the challenges of tracking epidemiological trends across borders. While official PAHO records document a 13 percent increase in annual diagnoses, broader analytical reports published by UNAIDS during the Rio de Janeiro conference estimated a 25 percent surge from 2010 through 2025. Experts attribute this steeper trajectory to systemic cuts in international funding for community prevention outreach.
Despite minor differences in percentage calculations, public health agencies universally agree on the demographic trends governing current transmission patterns. Approximately 75 percent of all new annual infections detected throughout Latin America occur among men, with key vulnerable populations experiencing the highest risk levels.
Leadership Perspectives on Access and Local Production
Health officials have framed the newly signed accord as a direct response to longstanding regional inequities. PAHO Director Jarbas Barbosa noted that this initiative represents an important step toward reducing gaps in access
to cutting-edge biomedical innovations for historically underserved populations.
Representing the pharmaceutical manufacturer, Gilead commercial chief Johanna Mercier described the collaboration as a reflection of our shared commitment to helping countries move
from clinical breakthroughs to practical public health execution. Furthermore, company representatives confirmed ongoing discussions with Brazil's Ministry of Health to evaluate the feasibility of manufacturing the drug domestically.
Regulatory Approvals and Financial Uncertainties
Despite the formal announcement, several practical hurdles must be resolved before patients can access the injection at public clinics. None of the 14 Latin American states currently possess active regulatory authorization for lenacapavir as a PrEP regimen. Formal regulatory filings are currently under priority review by national health authorities in Brazil, Mexico, Peru, and Argentina, though approval timelines remain variable.
Determining final procurement costs through PAHO's joint mechanism remains another unresolved priority. Within the commercial market in the United States, Yeztugo carries an official list price exceeding $28,000 annually per patient. Negotiating steep bulk-purchase discounts will be essential to ensure public health systems can sustain wide-scale distribution.
This initiative coincides with broader global distribution commitments undertaken by Gilead alongside PEPFAR and the Global Fund to reach over three million people in resource-constrained environments by 2028. Through this unified purchasing agreement, Latin America takes a decisive step toward eliminating the access barrier that previously threatened to leave the region behind.
